From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

On 16 March 2024, New Delhi Police arrested Neeraj Chauhan and others for selling fake anti-cancer drugs to patients at a ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, Keytruda (pembrolizumab), for adults with resectable locally advanced head and ...

Hundreds of thousands of patients with advanced head and neck cancer could live years longer without the disease, thanks to a breakthrough immunotherapy drug, a new clinical trial suggests. The study ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

May 31 (Reuters) - Gilead Sciences' (GILD.O) Trodelvy in combination with Merck's (MRK.N) blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35 ...

Key Takeaways Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The ...